Drug intelligence / Profile preview

PB121

Development stage: Preclinical
Lead developer: PEG Biosciences
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes

Overview

PB121 is a cytokine-based immuno-oncology therapeutic developed by PEG Biosciences. It is specifically formulated to activate natural killer (NK) cells and T effector cells while modulating the immunosuppressive components of the tumor microenvironment. By stimulating these key immune cell populations, PB121 aims to enhance the body's natural anti-tumor response. As a cytokine formulation, it is classified as a biologic modality and is currently in early-stage development for the treatment of various cancers.

Beyond the preview

Go deeper on PB121.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PB121.

Explore the full profile